Lansoprazole prevents the progression of liver fibrosis in non‐alcoholic steatohepatitis model rats. (22nd January 2018)
- Record Type:
- Journal Article
- Title:
- Lansoprazole prevents the progression of liver fibrosis in non‐alcoholic steatohepatitis model rats. (22nd January 2018)
- Main Title:
- Lansoprazole prevents the progression of liver fibrosis in non‐alcoholic steatohepatitis model rats
- Authors:
- Nishi, Toshio
Yamamoto, Yuta
Yamagishi, Naoko
Iguchi, Mikitaka
Tamai, Hideyuki
Ito, Takao
Tsuruo, Yoshihiro
Ichinose, Masao
Kitano, Masayuki
Ueyama, Takashi - Abstract:
- Abstract: Objectives: We previously demonstrated that lansoprazole provided hepatoprotection in a drug‐induced hepatitis animal model partially through the Nrf2/HO‐1 pathway. Here, we examined whether lansoprazole could also provide hepatoprotection in a rat model of non‐alcoholic steatohepatitis (NASH). Methods: Six‐week‐old rats were fed a normal chow or a choline‐deficient amino acid‐defined (CDAA) diet to establish a rat model of NASH. The groups fed a CDAA diet for 5 weeks were subcutaneously administered either a vehicle or a lansoprazole suspension for 4 weeks beginning the second week of the experiment. Key findings: Bridging fibrosis was observed in the livers of almost all the NASH model rats (six of seven), but it was not always observed in NASH model rats (one of seven) continuously administered lansoprazole. The serum aspartate aminotransferase level elevated by the CDAA diet was significantly decreased following lansoprazole administration. Lansoprazole also increased the expression of Nrf2, but not HO‐1, in the liver of NASH model rats. Lansoprazole decreased the level of activated TGF‐β protein. Furthermore, interleukin‐6 gene and protein expression were decreased. Conclusions: Lansoprazole inhibits hepatic fibrogenesis, at least during the early stages, in CDAA diet‐induced NASH model rats. The mechanisms might be associated with cytokine suppression but not the inhibition of reactive oxygen species.
- Is Part Of:
- Journal of pharmacy and pharmacology. Volume 70:Number 3(2018)
- Journal:
- Journal of pharmacy and pharmacology
- Issue:
- Volume 70:Number 3(2018)
- Issue Display:
- Volume 70, Issue 3 (2018)
- Year:
- 2018
- Volume:
- 70
- Issue:
- 3
- Issue Sort Value:
- 2018-0070-0003-0000
- Page Start:
- 383
- Page End:
- 392
- Publication Date:
- 2018-01-22
- Subjects:
- IL‐6 -- non‐alcoholic steatohepatitis -- Nrf2 -- pump inhibitor drug -- TGF‐beta
Pharmacy -- Periodicals
Pharmacology -- Periodicals
615.1 - Journal URLs:
- https://academic.oup.com/jpp ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)2042-7158 ↗
http://onlinelibrary.wiley.com/ ↗
http://www.ingentaconnect.com/content/rpsgb/jpp ↗ - DOI:
- 10.1111/jphp.12870 ↗
- Languages:
- English
- ISSNs:
- 0022-3573
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5034.000000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 6058.xml